Literature DB >> 23545362

Treatment of breast cancer brain metastases.

Silvia Hofer1, Bernhard C Pestalozzi.   

Abstract

Breast cancer represents the second most frequent cause of brain metastases. Treatment planning should consider several tumor and patient factors to estimate prognosis based on the Karnofsky Performance Status (KPS), age, extent of extra-cerebral disease as well as genetic subtype. When systemic disease is under control patients with up to three metastases qualify for local therapy, such as surgical excision or stereotactic radiotherapy. After the local treatment the addition of whole brain radiation therapy may be postponed until disease progression in the brain is observed and overall survival will not be compromised. Asymptomatic brain metastases may be first approached with a systemic treatment to which the primary tumor is considered to be sensitive.
© 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Brain metastasis; Breast cancer; Genetic subtype; Local treatment; Prognosis; Systemic treatment

Mesh:

Year:  2013        PMID: 23545362     DOI: 10.1016/j.ejphar.2012.11.068

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  Validation and Development of a Modified Breast Graded Prognostic Assessment As a Tool for Survival in Patients With Breast Cancer and Brain Metastases.

Authors:  Ishwaria M Subbiah; Xiudong Lei; Jeffrey S Weinberg; Erik P Sulman; Mariana Chavez-MacGregor; Debu Tripathy; Rohan Gupta; Ankur Varma; Jay Chouhan; Richard P Guevarra; Vicente Valero; Mark R Gilbert; Ana M Gonzalez-Angulo
Journal:  J Clin Oncol       Date:  2015-05-18       Impact factor: 44.544

2.  Breast cancer subtype as a predictor for outcomes and control in the setting of brain metastases treated with stereotactic radiosurgery.

Authors:  Christopher S Grubb; Ashish Jani; Cheng-Chia Wu; Shumaila Saad; Yasir H Qureshi; Tavish Nanda; Andrew Yaeh; Tzlil Rozenblat; Michael B Sisti; Jeffrey N Bruce; Guy M McKhann; Sameer A Sheth; Jeraldine Lesser; Simon K Cheng; Steven R Isaacson; Andrew B Lassman; Eileen P Connolly; Tony J C Wang
Journal:  J Neurooncol       Date:  2015-11-28       Impact factor: 4.130

3.  Breast cancer subtype and stage are prognostic of time from breast cancer diagnosis to brain metastasis development.

Authors:  Anurag Saraf; Christopher S Grubb; Mark E Hwang; Cheng-Hung Tai; Cheng-Chia Wu; Ashish Jani; Matthew E Lapa; Jacquelyn I S Andrews; Sierra Vanderkelen; Steven R Isaacson; Adam M Sonabend; Sameer A Sheth; Guy M McKhann; Michael B Sisti; Jeffrey N Bruce; Simon K Cheng; Eileen P Connolly; Tony J C Wang
Journal:  J Neurooncol       Date:  2017-07-03       Impact factor: 4.130

4.  Local control of brain metastasis: treatment outcome of focal brain treatments in relation to subtypes.

Authors:  Jae Uk Chong; Sung Gwe Ahn; Hak Min Lee; Jong Tae Park; Seung Ah Lee; Seho Park; Joon Jeong; Seung Il Kim
Journal:  J Breast Cancer       Date:  2015-03-27       Impact factor: 3.588

5.  NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer.

Authors:  Chris E Adkins; Mohamed I Nounou; Tanvirul Hye; Afroz S Mohammad; Tori Terrell-Hall; Neel K Mohan; Michael A Eldon; Ute Hoch; Paul R Lockman
Journal:  BMC Cancer       Date:  2015-10-13       Impact factor: 4.430

6.  SEOM clinical guidelines in metastatic breast cancer 2015.

Authors:  J Gavilá; S Lopez-Tarruella; C Saura; M Muñoz; M Oliveira; L De la Cruz-Merino; S Morales; I Alvarez; J A Virizuela; M Martin
Journal:  Clin Transl Oncol       Date:  2015-12-18       Impact factor: 3.405

7.  Apparent diffusion coefficient histogram in breast cancer brain metastases may predict their biological subtype and progression.

Authors:  Sung Jun Ahn; Mijin Park; Sungkyu Bang; Eunseo Cho; Sung Gwe Ahn; Sang Hyun Suh; Jong-Min Lee
Journal:  Sci Rep       Date:  2018-07-02       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.